CRISPR-mediated Mutation Correction of Hematopoietic Stem Cells from Patients with X-linked Chronic Granulomatous Disease Using Non-Viral Cell Engineering

2020-07-07T16:05:23+00:00May 16th, 2020|Comments Off on CRISPR-mediated Mutation Correction of Hematopoietic Stem Cells from Patients with X-linked Chronic Granulomatous Disease Using Non-Viral Cell Engineering

CRISPR-mediated Gene Editing Using a cGMP-Compliant Non-viral Cell Engineering: From iPSC Disease Modeling to Clinically-Meaningful Correction of Monogenic Disease Mutations in Patient Cells

2020-07-10T15:47:11+00:00May 12th, 2020|Comments Off on CRISPR-mediated Gene Editing Using a cGMP-Compliant Non-viral Cell Engineering: From iPSC Disease Modeling to Clinically-Meaningful Correction of Monogenic Disease Mutations in Patient Cells

Advancing Next Generation Cell and Gene Therapies to the Clinic Using Non-viral, Scalable Engineering and Genome Modification of Human Primary Cells, Stem Cells and iPSCs.

2020-07-07T17:05:49+00:00May 12th, 2020|0 Comments

GMP-compliant Non-viral CRISPR-mediated Process Correcting the Sickle Cell Disease Mutation in SCD Patient CD34+ Cells Achieves 60% Wild Type Adult Hemoglobin Expression in Differentiated Erythrocytes.

2020-07-07T22:14:04+00:00May 12th, 2020|Comments Off on GMP-compliant Non-viral CRISPR-mediated Process Correcting the Sickle Cell Disease Mutation in SCD Patient CD34+ Cells Achieves 60% Wild Type Adult Hemoglobin Expression in Differentiated Erythrocytes.
Go to Top